Opinion|Videos|March 14, 2025
Treatment Insights From RESPONSE: Ruxolitinib Therapy in Hydroxyurea-Resistant/Intolerant Disease
Author(s)Daniel Landau, MD
An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea-resistant/intolerant polycythemia vera (PV), have enhanced the treatment approach for patients with inadequate response to hydroxyurea.
Advertisement
Episodes in this series
Video content above is prompted by the following:
The phase 3 RESPONSE trial findings showed high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea-resistant/intolerant PV (
Advertisement
Related to this article
Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.
Short-course neoadjuvant botensilimab plus balstilimab drives deep responses in resectable pMMR and dMMR colon cancer, with ctDNA clearance and no recurrences.
The FDA granted final approval to Alembic's generic venetoclax tablets, rated therapeutically equivalent to Venclexta, for CLL/SLL and newly diagnosed AML.
Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.
Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for first-line MSI-H/dMMR mCRC.
The first-in-class oral RIPTAC molecule JNJ-6143 reached a 75% overall response rate and significant declines in PSA in metastatic castration-resistant prostate cancer.
Real-world study shows outpatient tarlatamab for relapsed SCLC is feasible, with mostly low-grade CRS, rare ICANS, low ICU use, and similar disease control.
In an interview, David J. Benjamin, MD, explains the findings on gender makeup of NCCN guideline panels he presented at the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
2
Lonardi on Overall Survival With Nivolumab/Ipilimumab in MSI-H/dMMR mCRC
3
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
4
JNJ-6143 Elicits PSA Responses in Heavily Pretreated mCRPC
5